Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): The Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial

[1]  H. Friess,et al.  PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): The MUNICON-II study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Schnider,et al.  Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  V. Rusch,et al.  Predictive Value of Initial PET-SUVmax in Patients with Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  M. Stuschke,et al.  Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Feith,et al.  Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center , 2009, Annals of Surgical Oncology.

[6]  J. Ajani,et al.  Influence of the baseline 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation , 2009, Cancer.

[7]  F. Lordick,et al.  Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Schwaiger,et al.  Induction Chemotherapy in Barrett Cancer: Influence on Surgical Risk and Outcome , 2007, Annals of surgery.

[9]  Wolfgang A Weber,et al.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.

[10]  K. Rufibach,et al.  Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Ychou,et al.  Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts? , 2007, Current opinion in oncology.

[12]  Val Gebski,et al.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.

[13]  M. Schwaiger,et al.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[15]  M. Schwaiger,et al.  Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[17]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Cheng,et al.  Classification of adenocarcinoma of the oesophagogastric junction , 1999, The British journal of surgery.

[19]  J. Ajani,et al.  Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. , 1998, The New England journal of medicine.

[20]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[21]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[22]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[23]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[24]  D. Parkin.  International variation , 2004, Oncogene.